Photo courtesy of OrPro Therapeutics.
OrPro Therapeutics is developing ORP100S, a novel biologic therapy to treat inflammation and obstruction in the lung associated with both chronic airway disorders and progression to severe COVID-19 disease caused by SARS-CoV-2 infection.

Photo courtesy of OrPro Therapeutics. OrPro Therapeutics is developing ORP100S, a novel biologic therapy to treat inflammation and obstruction in the lung associated with both chronic airway disorders and progression to severe COVID-19 disease caused by SARS-CoV-2 infection.

San Diego’s OrPro Therapeutics on May 28 announced plans that it is expanding its technology platform for treatment of airway diseases including cystic fibrosis (CF) and other immediate threats posed by the coronavirus...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99